BBR 3464

Drug Profile

BBR 3464

Alternative Names: BBR-3464

Latest Information Update: 09 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Gastric cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 22 Jan 2007 No development reported - Preclinical for Cancer in Italy (unspecified route)
  • 01 Sep 2005 BBR 3464 is still undergoing reformulation studies
  • 15 Dec 2004 A study has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top